Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELEST: Upadacitinib Induction in Crohn's Disease
NCT02365649Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc.. Started Mar 2015; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02365649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365649.